BridgeMD
3TR-PARTNER-RA
EU CTIS ID: 2024-511470-79-00
What this study is testing
To determine whether synovial molecular profiles, specifically the presence of CD80/CD86 biomarkers, can predict the clinical response to abatacept treatment in patients with early rheumatoid arthritis (RA).
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adults (female and male) aged 18 or over.
- Willing and capable of giving informed consent
- 2010 ACR / EULAR classification criteria for a diagnosis of Rheumatoid Arthritis* (* The ACR/EULAR classification for a diagnosis of RA could have been at any time in the patient’s disease history; the score does not need to be 6 or more at screening.)
- Symptom duration of <12 months
- At least one swollen joint, which is amenable to synovial biopsy (minimum grade 2 synovial thickening, as assessed at the biopsy visit)
- Moderate and severe Disease Activity (DAS28>3.2)
You likely can't join if
- Patients unable to tolerate synovial biopsy or in whom this is contraindicated including patients on anti-coagulants (e.g. warfarin). Patients on short-acting direct oral anticoagulant agents can be considered when anti-coagulant can be temporarily stopped, in line with local guidelines for procedures with a low risk of bleeding, taking into account the individual thromboembolic risk. Oral anti-platelet agents are permitted.
- Subject has a history or known presence of recurrent or chronic infection (eg, hepatitis B virus [HBV], hepatitis C virus [HCV], human immunodeficiency virus HIV]; recurrent urinary tract infections are allowed.
- Subjects testing positive for acute or chronic hepatitis A, B, or C, unless they are indicative of prior hepatitis B vaccination or cured hepatitis A or B and accompanied by normal liver transaminase values.
- Septic arthritis of a native joint within the last 12 months
- Septic arthritis of a prosthetic joint within 12 months or indefinitely if the joint remains in situ
- Latent TB infection unless they have completed adequate antibiotic prophylaxis
See the full eligibility criteria
Who can join
- Adults (female and male) aged 18 or over.
- Willing and capable of giving informed consent
- 2010 ACR / EULAR classification criteria for a diagnosis of Rheumatoid Arthritis* (* The ACR/EULAR classification for a diagnosis of RA could have been at any time in the patient’s disease history; the score does not need to be 6 or more at screening.)
- Symptom duration of <12 months
- At least one swollen joint, which is amenable to synovial biopsy (minimum grade 2 synovial thickening, as assessed at the biopsy visit)
- Moderate and severe Disease Activity (DAS28>3.2)
- No prior DMARD therapies (conventional, targeted or biologic DMARDs)
- Patient is judged by the supervising clinician to be a suitable candidate based upon medical history, physical examination, vital signs, and routine laboratory tests.
- Willing and able to comply with scheduled visits, laboratory tests, and other study procedures.
What rules you out
- Patients unable to tolerate synovial biopsy or in whom this is contraindicated including patients on anti-coagulants (e.g. warfarin). Patients on short-acting direct oral anticoagulant agents can be considered when anti-coagulant can be temporarily stopped, in line with local guidelines for procedures with a low risk of bleeding, taking into account the individual thromboembolic risk. Oral anti-platelet agents are permitted.
- Subject has a history or known presence of recurrent or chronic infection (eg, hepatitis B virus [HBV], hepatitis C virus [HCV], human immunodeficiency virus HIV]; recurrent urinary tract infections are allowed.
- Subjects testing positive for acute or chronic hepatitis A, B, or C, unless they are indicative of prior hepatitis B vaccination or cured hepatitis A or B and accompanied by normal liver transaminase values.
- Septic arthritis of a native joint within the last 12 months
- Septic arthritis of a prosthetic joint within 12 months or indefinitely if the joint remains in situ
- Latent TB infection unless they have completed adequate antibiotic prophylaxis
- Receipt of live vaccine <3 months prior to first dose of study medication
- Major surgery in 3 months prior to first dose of study medication
- Presence of a transplanted organ (with the exception of a corneal transplant >3 months prior to screening).
- Known recent substance abuse (drug or alcohol).
- Patients currently recruited to other clinical trials or taking part in a CTIMP study in the previous 4 months.
- Patients in whom there is no suitable joint for biopsy
- Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study. This should include assessment of risk factors for known clinically important risks associated with a study drug.
- Patients with severe hepatic impairment (Child Pugh C classification).
- Patients that are primary or secondary immunodeficiency (history of or currently active).
- Poor tolerability of venepuncture or lack of adequate venous access for required blood sampling during the study period.
- Women who are pregnant or breast-feeding.
- Women of child-bearing potential or males whose partners are women of child-bearing potential, unwilling to use an effective method of contraception (recommend double contraception) throughout the trial and beyond the end of trial treatment for the duration as defined in the relevant SmPC
- Individuals who are unable to give informed consent for any reason (vulnerable groups).
- Hypersensitivity to the active substance or to any of the excipients of abatacept or methotrexate, or any other contraindications to the study medications, as per the current SmPC
- History of or current primary inflammatory joint disease or primary rheumatological autoimmune disease other than RA (if secondary to RA, then the patient is still eligible)
- Prior exposure to any conventional/biologic/targeted DMARDs for RA
- Treatment with any investigational agent ≤ 8 weeks prior to baseline or < 5 half-lives of the investigational drug (whichever is the longer)
- Intra-articular or parenteral corticosteroids, or oral prednisolone more than 10mg/d or equivalent ≤ 4 weeks prior to screening visit
- Patients with a serious underlying medical disorder (e.g., end stage renal disease).
- Active infection
The study team makes the final eligibility decision.
Where it's taking place
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.